IDH1 and central nervous system cancer: Based on the clinical data at this stage, several significant issues need to be carefully evaluated for future development of IDH mutant inhibitors in glioma, including the ability to penetrate the BBB, the direct drug toxicity, and the severe adverse events (AEs).